Zkusit zdarma
Vaxcyte, Inc.

Vaxcyte, Inc.

PCVX
Cena:
$ 47.30
-0.09 (-0.19%)
Valuace
70
Růst
0
Zdraví
75
Souhrn Finanční data Pro investory Předpovědi Zprávy Dividendy Zisky Návštěvnost webu Akcionáři
Souhrn
Finanční data
Pro investory
Předpovědi
Zprávy
Dividendy
Zisky
Návštěvnost webu
Akcionáři

Zprávy

Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
Vaxcyte, Inc. (PCVX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Vaxcyte, Inc. (PCVX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

19:10 12-05-2026

Vaxcyte, Inc. (PCVX) Presents at Bank of America Global Healthcare Conference 2026 Transcript...

Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update

Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update

16:05 06-05-2026

Enrollment Now Completed for OPUS-1, OPUS-2 and OPUS-3 Phase 3 Trials Evaluating VAX-31 for the Prev...

Vaxcyte's Manufacturing-Backed Vaccine Platform Is Redefining The PCV Market

Vaxcyte's Manufacturing-Backed Vaccine Platform Is Redefining The PCV Market

22:59 01-05-2026

Vaxcyte is evolving from a single-product biotech into a commercial vaccine platform with advanced m...

Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference

Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference

16:05 07-04-2026

SAN CARLOS, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stag...

Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

8:30 23-03-2026

OPUS-1 Phase 3 Study Designed to Establish a New Standard for Adult Pneumococcal Conjugate Vaccines ...

Bridgefront Capital LLC Increases Stock Holdings in Vaxcyte, Inc. $PCVX

Bridgefront Capital LLC Increases Stock Holdings in Vaxcyte, Inc. $PCVX

4:50 16-03-2026

Bridgefront Capital LLC boosted its holdings in shares of Vaxcyte, Inc. (NASDAQ: PCVX) by 127.2% dur...

Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

16:05 24-02-2026

Comprehensive VAX-31 Adult Phase 3 Clinical Program, Finalized in Consultation and Alignment with FD...

Vaxcyte, Inc. $PCVX Shares Sold by China Universal Asset Management Co. Ltd.

Vaxcyte, Inc. $PCVX Shares Sold by China Universal Asset Management Co. Ltd.

4:29 21-02-2026

China Universal Asset Management Co. Ltd. lessened its holdings in shares of Vaxcyte, Inc. (NASDAQ: ...

Vaxcyte Spotlights VAX-31 Phase 3 Launch, Eyes Adult BLA by End of Next Year at Biotech Summit

Vaxcyte Spotlights VAX-31 Phase 3 Launch, Eyes Adult BLA by End of Next Year at Biotech Summit

2:05 16-02-2026

Vaxcyte (NASDAQ: PCVX) executives used a presentation at an annual biotech summit to highlight progr...

Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines

Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines

16:05 11-02-2026

Company Expects to Report Topline Data from OPUS-3 Trial and OPUS-2 Phase 3 Trial Evaluating Concomi...

Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026

Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026

16:05 10-02-2026

SAN CARLOS, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage...

Vaxcyte, Inc. $PCVX Shares Bought by Federated Hermes Inc.

Vaxcyte, Inc. $PCVX Shares Bought by Federated Hermes Inc.

4:02 08-02-2026

Federated Hermes Inc. raised its position in Vaxcyte, Inc. (NASDAQ: PCVX) by 6,856.3% in the undefin...

Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit

Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit

16:05 05-02-2026

SAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage...

Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

16:05 02-02-2026

SAN CARLOS, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage...

Vaxcyte Announces Pricing of $550 Million Public Offering

Vaxcyte Announces Pricing of $550 Million Public Offering

23:33 29-01-2026

SAN CARLOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage...

Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

16:06 29-01-2026

SAN CARLOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage...

Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine

Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine

17:00 22-01-2026

VAX-31 Adult Indication: Vaxcyte Doses First Participants in Phase 3 Study Evaluating Concomitant Ad...

SG Americas Securities LLC Buys 14,421 Shares of Vaxcyte, Inc. $PCVX

SG Americas Securities LLC Buys 14,421 Shares of Vaxcyte, Inc. $PCVX

6:23 20-01-2026

SG Americas Securities LLC increased its stake in Vaxcyte, Inc. (NASDAQ: PCVX) by 129.5% in the thir...

Vaxcyte, Inc. (NASDAQ:PCVX) Given Consensus Rating of “Moderate Buy” by Brokerages

Vaxcyte, Inc. (NASDAQ:PCVX) Given Consensus Rating of “Moderate Buy” by Brokerages

1:22 16-01-2026

Vaxcyte, Inc. (NASDAQ: PCVX - Get Free Report) has earned an average recommendation of "Moderate Buy...

Vaxcyte's Chief Technical Ops Officer Sells Shares

Vaxcyte's Chief Technical Ops Officer Sells Shares

10:17 03-01-2026

The CTO sold 9,743 shares. The sale represented 28.9% of Dhaliwal's holdings....

close

VAXCYTE DOSES FIRST PARTICIPANTS IN OPUS-3 PHASE 3 TRIAL EVALUATING VAX-31 IN ADULTS PREVIOUSLY VACCINATED WITH LOWER-VALENCY PNEUMOCOCCAL VACCINES

11-02-2026
COMPANY EXPECTS TO REPORT TOPLINE DATA FROM OPUS-3 TRIAL AND OPUS-2 PHASE 3 TRIAL EVALUATING CONCOMI...
Více zde

VAXCYTE TO REPORT FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDE BUSINESS UPDATE ON FEBRUARY 24, 2026

10-02-2026
SAN CARLOS, CALIF., FEB. 10, 2026 (GLOBE NEWSWIRE) -- VAXCYTE, INC. (NASDAQ: PCVX), A CLINICAL-STAGE...
Více zde

VAXCYTE TO PRESENT AT THE GUGGENHEIM EMERGING OUTLOOK: BIOTECH SUMMIT

05-02-2026
SAN CARLOS, CALIF., FEB. 05, 2026 (GLOBE NEWSWIRE) -- VAXCYTE, INC. (NASDAQ: PCVX), A CLINICAL-STAGE...
Více zde

VAXCYTE ANNOUNCES CLOSING OF $632.5 MILLION PUBLIC OFFERING INCLUDING FULL EXERCISE OF UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES

02-02-2026
SAN CARLOS, CALIF., FEB. 02, 2026 (GLOBE NEWSWIRE) -- VAXCYTE, INC. (NASDAQ: PCVX), A CLINICAL-STAGE...
Více zde

VAXCYTE ANNOUNCES PRICING OF $550 MILLION PUBLIC OFFERING

29-01-2026
SAN CARLOS, CALIF., JAN. 29, 2026 (GLOBE NEWSWIRE) -- VAXCYTE, INC. (NASDAQ: PCVX), A CLINICAL-STAGE...
Více zde

VAXCYTE ANNOUNCES COMMENCEMENT OF PROPOSED PUBLIC OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS

29-01-2026
SAN CARLOS, CALIF., JAN. 29, 2026 (GLOBE NEWSWIRE) -- VAXCYTE, INC. (NASDAQ: PCVX), A CLINICAL-STAGE...
Více zde

VAXCYTE ADVANCES ADULT AND INFANT PROGRAMS FOR VAX-31, A POTENTIAL BEST-IN-CLASS, NEXT-GENERATION PNEUMOCOCCAL CONJUGATE VACCINE

22-01-2026
VAX-31 ADULT INDICATION: VAXCYTE DOSES FIRST PARTICIPANTS IN PHASE 3 STUDY EVALUATING CONCOMITANT AD...
Více zde

VAXCYTE DOSES FIRST PARTICIPANTS IN THE OPUS PHASE 3, NONINFERIORITY TRIAL EVALUATING VAX-31 FOR THE PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE AND PNEUMONIA IN ADULTS

08-12-2025
TRIAL DESIGN FINALIZED IN CONSULTATION AND ALIGNMENT WITH U.S. FOOD AND DRUG ADMINISTRATION  STUDY ...
Více zde

VAXCYTE REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE INCLUDING FINAL DATA FROM POSITIVE VAX-24 INFANT PHASE 2 DOSE-FINDING STUDY

04-11-2025
FINAL DATA FROM VAX-24 INFANT PHASE 2 DOSE-FINDING STUDY CONSISTENT WITH PREVIOUSLY REPORTED POSITIV...
Více zde

VAXCYTE TO ESTABLISH FILL-FINISH MANUFACTURING IN NORTH CAROLINA AS KEY ELEMENT OF LONG-TERM UNITED STATES COMMERCIAL SUPPLY STRATEGY REPRESENTING UP TO $1 BILLION IN MANUFACTURING AND SERVICES

30-09-2025
NEW AGREEMENT WITH THERMO FISHER SCIENTIFIC EXPANDS DOMESTIC CAPACITY TO SUPPORT FUTURE COMMERCIAL M...
Více zde

VAXCYTE ADVANCES VAX-31 INFANT PHASE 2 DOSE-FINDING STUDY WITH FIRST PARTICIPANTS RECEIVING VAX-31 OPTIMIZED DOSE

03-09-2025
VAX-31 OPTIMIZED DOSE, WITH MAJORITY OF SEROTYPES DOSED AT 4.4MCG AND BALANCE AT 3.3MCG, IS DESIGNED...
Více zde

VAXCYTE REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE, HIGHLIGHTING KEY CLINICAL AND REGULATORY PROGRESS FOR VAX-31, A POTENTIAL BEST-IN-CLASS PNEUMOCOCCAL CONJUGATE VACCINE (PCV)

06-08-2025
FOLLOWING INTERACTIONS WITH FDA ON VAX-31 ADULT PROGRAM, INCLUDING END-OF-PHASE 2 MEETING, COMPANY F...
Více zde

VAXCYTE REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

07-05-2025
-- COMPANY REPORTED POSITIVE TOPLINE SAFETY, TOLERABILITY AND IMMUNOGENICITY DATA FROM PHASE 2 DOSE-...
Více zde

VAXCYTE APPOINTS DR. OLIVIER BRANDICOURT TO BOARD OF DIRECTORS

01-05-2025
SAN CARLOS, CALIF., MAY 01, 2025 (GLOBE NEWSWIRE) -- VAXCYTE, INC. (NASDAQ: PCVX), A VACCINE INNOVAT...
Více zde

VAXCYTE ANNOUNCES POSITIVE TOPLINE RESULTS FROM VAX-24 INFANT PHASE 2 DOSE-FINDING STUDY

31-03-2025
-- AT ALL DOSES EVALUATED, VAX-24 WAS WELL-TOLERATED AND DEMONSTRATED A SAFETY AND TOLERABILITY PROF...
Více zde

VAXCYTE TO HOST WEBCAST AND CONFERENCE CALL TO PRESENT TOPLINE RESULTS FROM VAX-24 INFANT PHASE 2 STUDY

30-03-2025
SAN CARLOS, CALIF., MARCH 30, 2025 (GLOBE NEWSWIRE) -- VAXCYTE, INC. (NASDAQ: PCVX), A CLINICAL-STAG...
Více zde

VAXCYTE REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

25-02-2025
-- COMPLETED SUCCESSFUL VAX-31 PHASE 2 ADULT PROGRAM; COMPANY REMAINS ON TRACK TO INITIATE VAX-31 AD...
Více zde

VAXCYTE TO REPORT FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS ON FEBRUARY 25, 2025

12-02-2025
SAN CARLOS, CALIF., FEB. 12, 2025 (GLOBE NEWSWIRE) -- VAXCYTE, INC. (NASDAQ: PCVX), A CLINICAL-STAGE...
Více zde

VAXCYTE ADVANCES TO SECOND STAGE OF ONGOING PHASE 2 STUDY EVALUATING VAX-31 FOR THE PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE IN INFANTS

05-02-2025
-- ADVANCEMENT TO STAGE 2 OF INFANT STUDY SUPPORTED BY REVIEW OF STAGE 1 SAFETY AND TOLERABILITY DAT...
Více zde

VAXCYTE TO PRESENT AT THE GUGGENHEIM SMID CAP BIOTECH CONFERENCE

30-01-2025
SAN CARLOS, CALIF., JAN. 30, 2025 (GLOBE NEWSWIRE) -- VAXCYTE, INC. (NASDAQ: PCVX), A CLINICAL-STAGE...
Více zde

KUEHN LAW ENCOURAGES INVESTORS OF VAXCYTE, INC. TO CONTACT LAW FIRM

30-01-2025
NEW YORK, JAN. 30, 2025 (GLOBE NEWSWIRE) -- KUEHN LAW, PLLC, A SHAREHOLDER LITIGATION LAW FIRM, IS I...
Více zde

KUEHN LAW ENCOURAGES INVESTORS OF VAXCYTE, INC. TO CONTACT LAW FIRM

07-01-2025
NEW YORK , JAN. 7, 2025 /PRNEWSWIRE/ -- KUEHN LAW, PLLC, A SHAREHOLDER LITIGATION LAW FIRM, IS INVES...
Více zde

KUEHN LAW ENCOURAGES INVESTORS OF VAXCYTE, INC. TO CONTACT LAW FIRM

19-12-2024
NEW YORK, DEC. 19, 2024 (GLOBE NEWSWIRE) -- KUEHN LAW, PLLC, A SHAREHOLDER LITIGATION LAW FIRM, IS I...
Více zde

VAXCYTE INITIATES PHASE 2 STUDY EVALUATING VAX-31 FOR THE PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE IN INFANTS

03-12-2024
-- COMPANY EXPECTS TO ANNOUNCE VAX-31 INFANT STUDY TOPLINE SAFETY, TOLERABILITY AND IMMUNOGENICITY D...
Více zde

VAXCYTE PROVIDES POSITIVE REGULATORY UPDATES ON VAX-31 PEDIATRIC AND ADULT PROGRAMS

12-11-2024
-- VAX-31 INFANT INDICATION: INVESTIGATIONAL NEW DRUG APPLICATION CLEARED BY FDA; COMPANY EXPECTS TO...
Více zde

VAXCYTE REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

05-11-2024
-- COMPANY REPORTED POSITIVE TOPLINE SAFETY, TOLERABILITY AND IMMUNOGENICITY DATA FROM PHASE 1/2 STU...
Více zde

VAXCYTE TO PRESENT AT THE 2024 CANTOR GLOBAL HEALTHCARE CONFERENCE

11-09-2024
SAN CARLOS, CALIF., SEPT. 11, 2024 (GLOBE NEWSWIRE) -- VAXCYTE, INC. (NASDAQ: PCVX), A CLINICAL-STAG...
Více zde

VAXCYTE ANNOUNCES CLOSING OF $1.5 BILLION PUBLIC OFFERING INCLUDING FULL EXERCISE OF UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES

06-09-2024
SAN CARLOS, CALIF., SEPT. 06, 2024 (GLOBE NEWSWIRE) -- VAXCYTE, INC. (NASDAQ: PCVX), A CLINICAL-STAG...
Více zde

VAXCYTE ANNOUNCES PRICING OF $1.3 BILLION PUBLIC OFFERING

04-09-2024
SAN CARLOS, CALIF., SEPT. 04, 2024 (GLOBE NEWSWIRE) -- VAXCYTE, INC. (NASDAQ: PCVX), A CLINICAL-STAG...
Více zde

VAXCYTE ANNOUNCES COMMENCEMENT OF PROPOSED PUBLIC OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS

03-09-2024
SAN CARLOS, CALIF., SEPT. 03, 2024 (GLOBE NEWSWIRE) -- VAXCYTE, INC. (NASDAQ: PCVX), A CLINICAL-STAG...
Více zde

close

Datum Typ Otevřít EDGAR Stáhnout dokument
2026-02-02 00:00:008-KStáhnout
2025-12-19 00:00:008-KStáhnout
2025-11-04 00:00:008-KStáhnout
2025-11-04 00:00:0010-QStáhnout
2025-09-30 01:00:008-KStáhnout
2025-09-30 00:00:008-KStáhnout
2025-08-06 01:00:008-KStáhnout
2025-08-06 01:00:0010-QStáhnout
2025-08-06 00:00:008-KStáhnout
2025-08-06 00:00:0010-QStáhnout
2025-06-17 01:00:008-KStáhnout
2025-06-17 00:00:008-KStáhnout
2025-05-07 01:00:008-KStáhnout
2025-05-07 01:00:0010-QStáhnout
2025-05-07 00:00:008-KStáhnout
2025-05-07 00:00:0010-QStáhnout
2025-05-01 01:00:008-KStáhnout
2025-05-01 00:00:008-KStáhnout
2025-03-31 01:00:008-KStáhnout
2025-03-31 00:00:008-KStáhnout
2025-02-25 00:00:008-KStáhnout
2025-02-25 00:00:0010-KStáhnout
2025-02-24 23:00:008-KStáhnout
2025-02-24 23:00:0010-KStáhnout
2024-11-21 00:00:008-KStáhnout
2024-11-20 23:00:008-KStáhnout
2024-11-05 00:00:008-KStáhnout
2024-11-05 00:00:0010-QStáhnout
2024-11-04 23:00:008-KStáhnout
2024-11-04 23:00:0010-QStáhnout
2024-09-06 01:00:008-KStáhnout
2024-09-06 00:00:008-KStáhnout
2024-09-03 01:00:008-KStáhnout
2024-09-03 00:00:008-KStáhnout
2024-08-06 01:00:008-KStáhnout
2024-08-06 01:00:0010-QStáhnout
2024-08-06 00:00:008-KStáhnout
2024-08-06 00:00:0010-QStáhnout
2024-07-02 01:00:008-KStáhnout
2024-07-02 00:00:008-KStáhnout
2024-06-10 01:00:008-KStáhnout
2024-06-10 00:00:008-KStáhnout
2024-05-08 01:00:008-KStáhnout
2024-05-08 01:00:0010-QStáhnout
2024-05-08 00:00:008-KStáhnout
2024-05-08 00:00:0010-QStáhnout
2024-02-27 00:00:008-KStáhnout
2024-02-27 00:00:0010-KStáhnout
2024-02-26 23:00:008-KStáhnout
2024-02-26 23:00:0010-KStáhnout
2024-01-31 00:00:008-KStáhnout
2024-01-30 23:00:008-KStáhnout
2023-11-28 00:00:008-KStáhnout
2023-11-27 23:00:008-KStáhnout
2023-11-27 00:00:008-KStáhnout
2023-11-26 23:00:008-KStáhnout
2023-11-06 00:00:008-KStáhnout
2023-11-06 00:00:0010-QStáhnout
2023-11-05 23:00:008-KStáhnout
2023-11-05 23:00:0010-QStáhnout
2023-10-16 01:00:008-KStáhnout
2023-10-16 00:00:008-KStáhnout
2023-10-04 01:00:008-KStáhnout
2023-10-04 00:00:008-KStáhnout
2023-09-07 01:00:008-KStáhnout
2023-09-07 00:00:008-KStáhnout
2023-08-08 01:00:008-KStáhnout
2023-08-08 01:00:0010-QStáhnout
2023-08-08 00:00:008-KStáhnout
2023-08-08 00:00:0010-QStáhnout
2023-06-15 01:00:008-KStáhnout
2023-06-15 00:00:008-KStáhnout
2023-05-08 01:00:008-KStáhnout
2023-05-08 01:00:0010-QStáhnout
2023-05-08 00:00:008-KStáhnout
2023-05-08 00:00:0010-QStáhnout
2023-04-20 01:00:008-KStáhnout
2023-04-20 00:00:008-KStáhnout
2023-04-17 01:00:008-KStáhnout
2023-04-17 00:00:008-KStáhnout
2023-03-06 00:00:008-KStáhnout
2023-03-05 23:00:008-KStáhnout
2023-02-27 00:00:008-KStáhnout
2023-02-27 00:00:0010-KStáhnout
2023-02-26 23:00:008-KStáhnout
2023-02-26 23:00:0010-KStáhnout
2022-12-20 00:00:008-KStáhnout
2022-12-19 23:00:008-KStáhnout
2022-12-12 00:00:008-KStáhnout
2022-12-11 23:00:008-KStáhnout
2022-11-07 00:00:008-KStáhnout
2022-11-07 00:00:0010-QStáhnout
2022-11-06 23:00:008-KStáhnout
2022-11-06 23:00:0010-QStáhnout
2022-10-27 01:00:008-KStáhnout
2022-10-27 00:00:008-KStáhnout
2022-10-24 01:00:008-KStáhnout
2022-10-24 00:00:008-KStáhnout
2022-08-08 01:00:008-KStáhnout
2022-08-08 01:00:0010-QStáhnout
2022-08-08 00:00:008-KStáhnout
2022-08-08 00:00:0010-QStáhnout
2022-06-07 01:00:008-KStáhnout
2022-06-07 00:00:008-KStáhnout
2022-05-09 01:00:008-KStáhnout
2022-05-09 01:00:0010-QStáhnout
2022-05-09 00:00:008-KStáhnout
2022-05-09 00:00:0010-QStáhnout
2022-04-18 01:00:008-KStáhnout
2022-04-18 00:00:008-KStáhnout
2022-02-28 00:00:008-KStáhnout
2022-02-28 00:00:0010-KStáhnout
2022-02-27 23:00:008-KStáhnout
2022-02-27 23:00:0010-KStáhnout
2022-01-13 00:00:008-KStáhnout
2022-01-12 23:00:008-KStáhnout
2021-11-10 00:00:008-KStáhnout
2021-11-10 00:00:0010-QStáhnout
2021-11-09 23:00:008-KStáhnout
2021-11-09 23:00:0010-QStáhnout
2021-10-28 01:00:008-KStáhnout
2021-10-28 00:00:008-KStáhnout
2021-09-20 01:00:008-KStáhnout
2021-09-20 00:00:008-KStáhnout
2021-08-11 01:00:008-KStáhnout
2021-08-11 01:00:0010-QStáhnout
2021-08-11 00:00:008-KStáhnout
2021-08-11 00:00:0010-QStáhnout
2021-06-03 01:00:008-KStáhnout
2021-06-03 00:00:008-KStáhnout
2021-05-11 01:00:008-KStáhnout
2021-05-11 01:00:0010-QStáhnout
2021-05-11 00:00:008-KStáhnout
2021-05-11 00:00:0010-QStáhnout
2021-03-29 01:00:008-KStáhnout
2021-03-29 01:00:0010-KStáhnout
2021-03-29 00:00:008-KStáhnout
2021-03-29 00:00:0010-KStáhnout
2021-03-25 00:00:008-KStáhnout
2021-03-24 23:00:008-KStáhnout
2021-01-25 00:00:008-KStáhnout
2021-01-24 23:00:008-KStáhnout
2020-12-22 00:00:008-KStáhnout
2020-12-21 23:00:008-KStáhnout
2020-11-12 00:00:008-KStáhnout
2020-11-12 00:00:0010-QStáhnout
2020-11-11 23:00:008-KStáhnout
2020-11-11 23:00:0010-QStáhnout
2020-08-12 01:00:008-KStáhnout
2020-08-12 01:00:0010-QStáhnout
2020-08-12 00:00:008-KStáhnout
2020-08-12 00:00:0010-QStáhnout
2020-06-16 01:00:008-KStáhnout
2020-06-16 00:00:008-KStáhnout
preloader